4.7 Article

Self-assembled tacrolimus-loaded lecithin-chitosan hybrid nanoparticles for in vivo management of psoriasis

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 608, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ijpharm.2021.121114

Keywords

Chitosan; Lecithin; Tacrolimus; Hybrid nanoparticles; Psoriasis; Topical

Ask authors/readers for more resources

Lecithin-chitosan hybrid nanoparticles show promise as a nanocarrier for drug delivery, with the ability to encapsulate hydrophobic drugs effectively and release them in the upper skin layers. Through the use of suitable techniques and co-solvents, these nanoparticles can optimize drug encapsulation and achieve desirable therapeutic effects.
Lecithin-chitosan hybrid nanoparticles are emerging as a promising nanocarrier for topical drug delivery. They could achieve a maximized encapsulation of hydrophobic drugs due to the lipophilic nature of lecithin that comprises the core while enhancing retention in the upper skin layers using the positively charged polymeric coat of chitosan. The aim of this study is to incorporate tacrolimus; a hydrophobic anti-proliferative agent into lecithin chitosan hybrid nanoparticles by ethanolic injection technique using a suitable co-solvent to enhance encapsulation of the drug and allow a satisfactory release profile in the upper skin layers. Tacrolimus was successfully incorporated into the synthesized particles using olive oil and Tween 80 as co-solvents, with particle size (160.9 nm +/- 15.9 and 118.7 nm +/- 13.3, respectively) and EE (88.27% +/- 4.3 and 66.72% +/- 1.8, respectively). The in vitro drug release profile showed a faster release pattern for the Tween 80-containing particles over a 48-hour period (79.98% vs. 35.57%), hence, were selected for further investigation. The hybrid nanoparticles achieved significantly higher skin deposition than the marketed product (63.51% vs. 34.07%) through a 24-hour time interval, particularly, to the stratum corneum and epidermis skin layers. The in vivo results on IMQ-mouse models revealed superior anti-psoriatic efficacy of the synthesized nanoparticles in comparison to the marketed product in terms of visual observation of the skin condition, PASI score and histopathological examination of autopsy skin samples. Additionally, the in vivo drug deposition showed superior skin deposition of the nanoparticles compared to the marketed product (74.9% vs. 13.4%).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available